Alex Gorsky, the CEO whose nine-year tenure at J&J was marred by law­suits over the com­pa­ny’s talc ba­by pow­der and opi­oids, will ...

→ An­oth­er cut of pos­i­tive in­ter­im da­ta have lift­ed ex­pec­ta­tions that Ad­verum’s gene ther­a­py that could give the an­ti-VEGF de­vel­op­ers … ...

DBV Tech­nolo­gies has all but so­lid­i­fied its run­ner up sta­tus in the race to bring a peanut al­ler­gy treat­ment on to the Unit­ed States mar­ket … ...

Big Phar­ma has lost yet an­oth­er top ex­ec­u­tive to the glossy ranks of small — but cash-rich — biotech, with Bill Hin­shaw, the for­mer head of US … ...

Weeks away from a po­ten­tial EUA ap­pli­ca­tion, Mod­er­na an­nounced they have com­plet­ed en­roll­ment in their 30,000-per­son Phase III Covid-19 vac­cine tri­al, with over a … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

A whole in­dus­try may have been born out of the spec­tac­u­lar suc­cess of CD19 CAR-T, push­ing the en­ve­lope on next-gen­er­a­tion con­structs hit­ting new tar­gets. But … ...

Three days af­ter Gilead’s Kite sub­sidiary showed off stel­lar da­ta on their num­ber 2 CAR-T KTE-X19 at ASH, the ex­ec­u­tive team has piv­ot­ed straight to the FDA with a BLA fil­ing and a shot at ...

The FDA forced Acel­Rx Phar­ma­ceu­ti­cals to go back to the draw­ing board to re­fash­ion a bet­ter safe­ty plan for its new pain ther­a­py Dsu­via … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

A pop­u­lar the­o­ry for how to treat some of the worst symp­toms of Covid-19 stum­bled to­day.

Sci­ence 37, one of the star­tups that fu­eled the rise in de­cen­tral­ized clin­i­cal tri­als, will go pri­vate and see its one-time $1 bil­lion val­u­a­tion evap­o­rate … ...